Reviewed by Michael Gill, B. Sc.
5 Symbicort Clinical Trials Near Me
Top Cities for Symbicort Clinical Trials
Image of San Diego in California.
San Diego
3Active Trials
Research SiteTop Active Site
Image of Saint Louis in Missouri.
Saint Louis
3Active Trials
Research SiteTop Active Site
Symbicort Clinical Trials by Phase of Trial
Phase 3 Symbicort Clinical Trials
4Active Symbicort Clinical Trials
4Number of Unique Treatments
195Number of Active Locations
Most Recent Symbicort Clinical Trials

What Are Symbicort Clinical Trials?

Symbicort is the brand name for the compound budesonide/formoterol, and is used in the treatment of both asthma and chronic obstructive pulmonary disease (COPD). Symbicort doesn’t have a long history, first being introduced in Sweden in 2000 and has become one of the most commonly prescribed drugs around the world.

Symbicort’s patent was granted by the FDA in 2006 and the European Union in 2014. Now, there are more than 12 million people in the United States alone that take Symbicort to treat asthma and COPD, with trials underway to expand the ailments that Symbicort can cover. The use of Symbicort has shown to be effective in up to 90 percent of asthma patients by the end of treatment and a 70 percent reduction in use of rescue inhalers.

Why is Symbicort Being Studied in Clinical Trials?

While Symbicort’s description says that it isn’t used to treat or prevent bronchospasm, recent studies have found that it may actually help. Because of this, the prescription count for Symbicort is likely to rise in the future as it’s used for more than just asthma and COPD. Studies are also set to determine how often rescue inhalers are still needed for patients that have been using Symbicort for years, as well as a possible increase in exercise parameters.

How Does Symbicort Treatment Work?

Symbicort is a combination of budesonide and formoterol. Budesonide is a corticosteroid that helps to reduce airway swelling and irritation, while formoterol is a beta agonist that relaxes the muscles of the airways. When combined, the two reduce symptoms of asthma and COPD when inhaled.

Symbicort should be used twice per day, with one puff in the morning and another in the evening at 12 hours apart, but does not replace a rescue inhaler. The most common side effects for Symbicort include body aches, cough, headache, sneezing and a stuffy or runny nose.

What are some of the breakthrough clinical trials involving Symbicort?

There have been several landmark studies involving Symbicort in recent years. Some of the most notable studies are:

2021: Combination with glycopyrronium - While Symbicort has proven to be very effective on its own, researchers are trying to determine if it may be even more effective when combined with glycopyrronium, a drug that is more commonly used in treatment of hyperhidrosis (severe sweating) and drooling. Over 2,000 people with asthma are taking part in this study across the United States.

2022: Comparison to BFF MDI 320/9.6 - Symbicort’s compound is TBH 320/9 while the drug that it was placed against in a 2022 comparison was BFF MDI 320/9.6. Studies are determining which one can be more effective in asthma treatment. There are four different treatment groups in total, with Symbicort users making up one of those four groups.

2008: Comparison to Advair - Just like Symbicort, Advair is a combination inhaler, though the compound construction is different as Advair combined fluticasone and salmeterol. Before Symbicort was introduced, Advair was much more commonly used, and this 2008 study pitted the two against each other to determine which one was more effective.

Who Are The Key Opinion Leaders On Symbicort Clinical Trial Research?

Rita Rubin, MA

Rita Rubin attended Harvard, Northwestern and Johns Hopkins Universities and has worked as a medical writer for nearly 40 years. Since 1998, Rubin has been a medical reporter for USA Today.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 13th, 2021

Last Reviewed: November 21st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.